Novavax's coronavirus vaccine shows 90% efficacy in late stage trial

Vaccine maker Novavax said Monday its shot was highly effective against Covid-19 and also protected against variants in a large, late-stage study in the US and Mexico. The vaccine was about 90 per cent effective overall and preliminary data showed it was safe, the company said.
While demand for Covid-19 shots in the US has dropped off dramatically, the need for more vaccines around the world remains critical. The Novavax vaccine, which is easy to store and transport, is expected to play an important role in boosting vaccine supplies in the developing world.